Let's take a look back.
Nonsense - Pharmaceuticals
Benefiting from local R&D demand: $Regeneron Pharma(REGN.US) Logic: Strong in-house R&D engine, focusing on ophthalmology, immunology, and oncology. Its independent innovation capability becomes an advantage amid the trend of reducing external dependence. Highlights: Strong sales of star products Eylea and Dupixent, with a deep R&D pipeline. $Vertex Pharma(VRTX.US) Logic: Holds an absolute monopoly in the cystic fibrosis (CF) field, with ample cash flow. Actively expanding into non-CF areas (e.g., pain, kidney diseases)...
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
